TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT05773079

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Toripalimab
Description: Within 4 to 12 weeks after the first line of treatment, the maintenance treatment of Toripalimab was started, and 240 mg of Toripalimab was injected intravenously every 3 weeks (the maintenance treatment time was not more than 1 year, until there was an intolerable toxic reaction, or disease progression, or withdrawal of consent, or the investigator judged that it was necessary to withdraw from the treatment, or the subject had received treprizumab treatment for a cumulative period of 1 year or other reasons specified in the protocol). During the treatment period, tumor imaging evaluation shall be conducted every 3 months to see the research process description for details, and the evaluation shall be conducted according to the evaluation criteria of recist. If the evaluation is progress, the treatment shall be stopped.
Study: NCT05020847

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Standard F75
Description: F-75 contains 75 kcal and 0.9 g protein per 100 ml

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Alternative F75 with CMV
Description: Alternative F75 With CMV contains cereal flour, oil, sugar, powdered milk with complex mineral-vitamin (CMV)

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Alternative F75 without CMV
Description: Alternative F75 without CMV contains cereal flour, oil, sugar, powdered milk without complex mineral vitamin (CMV).
Study: NCT05884853

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: PEERS
Description: The Program for the Education and Enrichment of Relational Skills (PEERS®) studies is an evidence-based 16-week group-based social skill training program developed for adolescents and young adults with ASD.

Intervention type: BEHAVIORAL
Group type: SHAM_COMPARATOR
Intervention: PEERS
Description: The Program for the Education and Enrichment of Relational Skills (PEERS®) studies is an evidence-based 16-week group-based social skill training program developed for adolescents and young adults with ASD.
Study: NCT05960526

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: extract Binahong
Description: Extract Binahong 2.5% as nasal irrigation solution

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Isotonic saline nasal irrigation
Description: NaCl 0.9% as nasal irrigation solution
Study: NCT04218903

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Combined training performed four times per week (CT4)
Description: CT4 will perform four combined training sessions per week throughout 12 weeks. Each session will be composed 10-15 minutes of resistance exercise (1-4 sets of 10-15 repetitions, using an intensity corresponding to 50-70%1RM in 3 exercises) followed by 20-25 minutes of aerobic exercise (walking or running at an intensity corresponding to 60-70% of VO2peak).

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Combined training performed two times per week (CT2)
Description: CT2 will perform two combined training sessions per week throughout 12 weeks. Each session will be composed 20-30 minutes of resistance exercise (1-4 sets of 10-15 repetitions, using an intensity corresponding to 50-70%1RM in 6 exercises) followed by 40-50 minutes of aerobic exercise (walking or running at an intensity corresponding to 60-70% of VO2peak).
Study: NCT05121233

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Diclofenac
Description: a single dose 75 mg IV diclofenac by infusion prior to the procedure

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: single dose iv placebo (saline ) by infusion prior to the procedure
Study: NCT04826809

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: N95 mask
Description: Standard 1870 N95 one time use mask

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Nordell single E-100 layer mask
Description: Nordell mask design using one layer of E-100 fabric plus cotton fabric overlay

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Nordell double E-100 layer mask
Description: Nordell mask design using two layers of E-100 fabric
Study: NCT05080751

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Eating Behaviors
Description: Materials to be weekly available for intervention group, following a schedule of sessions (six in total): videos, audios, booklets, films, books and other presentations. The intervention will be based online, in a asynchronous modality. Members will self-manage activities.
Study: NCT04799028

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Traditional cow's milk
Description: Fortified cow's milk

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Experimental milk
Description: Milk with synbiotics and fat blend

Intervention type: OTHER
Group type: OTHER
Intervention: Habitual diet
Description: Habitual diet
Study: NCT05096780

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Flavored caffeinated beverage
Description: 16.9 oz (500 cc), carbonated, zero calorie

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Flavored caffeinated beverage
Description: 16.9 oz (500 cc), carbonated, zero calorie

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Flavored caffeinated beverage
Description: 16.9 oz (500 cc), carbonated, zero calorie

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Flavored caffeinated beverage
Description: 16.9 oz (500 cc), carbonated, zero calorie
Study: NCT04688697

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: prepectoral implant-based reconstruction
Description: In this group, patients receive breast reconstruction with prosthesis placed to anterior pectoralis major, synthetic mesh is used to enclose the prosthesis and place it to anterior pectoralis major.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: subpectoral implant-based reconstruction
Description: In this group, patients receive breast reconstruction with placed to posterior pectoralis major, part of the mesh is placed under the pectoralis major during the operation, and the mesh is used to cover the suture of the prosthesis on the inferior plica, or to directly enclose the lower part of the implant.
Study: NCT05328713

Intervention type: DIAGNOSTIC_TEST
Intervention: Cardiac MRI
Description: This study will use Cardiac MRI to identify subclinical cardiac dysfunction.
Study: NCT04963309

Intervention type: OTHER
Intervention: endotracheal tube extubation in the operating room
Description: endotracheal tube extubation in the operating room
Study: NCT04820803

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: ORAL INTERVENTION WITH CETYLPYRIDINIUM CHLORIDE
Description: one mouthwash containing cetylpyridinium chloride (0.07%) for 60 seconds

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: PLACEBO
Description: one mouthwash containing distilled (placebo) water for 60 seconds
Study: NCT04351178

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Mobile phone supported and team based rehabilitation
Description: Participants in the intervention group will receive an 8-week mobile phone supported and team based rehabilitation intervention (F@ce 2.0).The participants will be introduced to a problem-solving strategy intended to facilitate the learning and problem-solving process to be used during the intervention. The strategy will provide a structure for healthcare professionals delivering the intervention. Three goals in daily activities will be formulated that the person wants and needs to do within the home environment. Each activity will be practiced together with the healthcare professionals and significant others. The significant others will be informed about the participant's goals and the planned strategies for reaching the goals. The participants will practice the activities in their home environment supported by mobile phone calls and text messages. In addition they will be given information about stroke.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Rehabilitation as usual
Description: Control group participants will receive rehabilitation as usual and in addition information about stroke.
Study: NCT06196060

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Visual perspective taking training
Description: Participants will be instructed to utilize small building blocks for the construction of diverse three-dimensional models, with a particular emphasis on employing various perspectives. The visual perspective taking training sessions will be conducted three times weekly over a period of 4 weeks.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Block building training
Description: Participants will be instructed to utilize unit building blocks to construct diverse three-dimensional models. The block building training sessions will be conducted three times weekly over a period of 4 weeks.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Thought-bubble training
Description: Participants will be instructed in the comprehension of mental states through the utilization of cartoon thought-bubbles as a representational tool. The thought-bubble training sessions will be conducted three times weekly over a period of 4 weeks.

Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Treatment as usual
Description: Participants will continue to receive treatment as usual during the trial.
Study: NCT06367829

Intervention type: PROCEDURE
Intervention: Lubinus SPII hip stem 130mm
Description: Shorter length of the SPII hip stem

Intervention type: PROCEDURE
Intervention: Lubinus SPII hip stem 150mm
Description: Longer length of the SPII hip stem
Study: NCT06254248

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Systemic therapy
Description: Atezolizumab-Bevacizumab every 3 weeks until progression or side effects in combination with Standardized immunosuppressive treatment:~Tacrolimus (objective 5-7 ng/ml) Mycophenolate Mofetil 1000 mg per day Corticosteroids at least 5 mg per day Everolimus will be continued if already started before the inclusion (objective 5-7 ng/ml). If everolimus has not been started prior to inclusion, do not start it, but adopt the following protocol: corticoids + Tacrolimus + Cellcept.
Study: NCT06114407

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Baricitinib 2mg
Description: Participants of arm 'A' will be treated with tablet baricitinib 2 mg twice daily for 12 weeks

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Tofacitinib 5 mg
Description: Participants of arm 'B' getting tablet tofacitinib 5 mg twice daily for 12 weeks will be taken as historical control arm from another study on the efficacy of tofacitinib in refractory axial spondyloarthritis
Study: NCT04856449

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Dialectical Behavioral Therapy Skills Training
Description: DBT skills training consists of a 6 months training in mindfulness, emotion regulation, interpersonal effectiveness and distress tolerance.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: EMDR
Description: EMDR sessions will be conducted to reprocess trauma-related memories.
Study: NCT05385068

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Niraparib
Description: Niraparib 200 or 300mg\* QD PO continually;~\*The starting dose of niraparib was individualized based on patients' bodyweight and baseline platelet count; 200 mg QD for Patients with baseline body weight \<77 kg or platelets count \<150,000/μL;300 mg QD for Patients with baseline body weight ≥77 kg and platelets count ≥150,000/μL.~For patients who had experienced grade 4 adverse events from previous use of PARPi, niraparib staring dose was 200 mg QD.~Anlotinib 10mg QD PO from Day 1 to 14 of every 21-day cycle
Study: NCT06413225

Intervention type: DEVICE
Intervention: Synergy cervical disc system
Description: motion preservation disc

Intervention type: DEVICE
Intervention: Synergy cervical disc system
Description: motion preservation disc
Study: NCT05011500

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Radiotherapy with Closed Mask
Description: Radiotherapy for head and neck cancer, using a closed mask (full thermoplastic mask) to restrict patient movement.

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Radiotherapy with Closed Mask
Description: Radiotherapy for head and neck cancer, using a closed mask (full thermoplastic mask) to restrict patient movement.

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Radiotherapy with Closed Mask
Description: Radiotherapy for head and neck cancer, using a closed mask (full thermoplastic mask) to restrict patient movement.

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Radiotherapy with Open Mask and Surface Scanning
Description: Radiotherapy for head and neck cancer, using an open mask to restrict patient movement. Surface Scanning is used to monitor patient movement/positioning.

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Radiotherapy with Open Mask and Surface Scanning
Description: Radiotherapy for head and neck cancer, using an open mask to restrict patient movement. Surface Scanning is used to monitor patient movement/positioning.

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Radiotherapy with Open Mask and Surface Scanning
Description: Radiotherapy for head and neck cancer, using an open mask to restrict patient movement. Surface Scanning is used to monitor patient movement/positioning.

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Radiotherapy with No Mask
Description: Radiotherapy for head and neck cancer, without using a mask to restrict patient movement. Surface Scanning is used to monitor patient movement/positioning.

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Radiotherapy with No Mask
Description: Radiotherapy for head and neck cancer, without using a mask to restrict patient movement. Surface Scanning is used to monitor patient movement/positioning.

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Radiotherapy with No Mask
Description: Radiotherapy for head and neck cancer, without using a mask to restrict patient movement. Surface Scanning is used to monitor patient movement/positioning.
Study: NCT06485219

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 11.2 mg/m2 Purinostat Mesylate
Description: Puesta Mesylate for Injection: Intravenous infusion, Phase IIa is administered on Days 1, 4, 8, and 11 of each cycle, with 3 weeks (21 days) as a single dosing cycle.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 15 mg/m2 Purinostat Mesylate
Description: Puesta Mesylate for Injection: Intravenous infusion, Phase IIa is administered on Days 1, 4, 8, and 11 of each cycle, with 3 weeks (21 days) as a single dosing cycle.
Study: NCT05233280

Intervention type: OTHER
Intervention: Oral liquids and soft food 2 hours postoperative
Description: Early versus delayed oral liquid feeding after ceasarean section
Study: NCT04764565

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Nuun Instant
Description: Contains (per 11 gram serving) the following: 7 grams of carbohydrate, calcium (20mg, 2%DV), sodium (520mg, 23%DV), potassium (385mg, 8%DV), magnesium (8mg, 2%DV), chloride (250mg, 10%DV), and 100% of vitamin C (90mg) and B12 (2.4 mcg).

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Water
Description: water

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Water
Description: water

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Water
Description: water

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Nuun Electrolyte
Description: Citric Acid, Dextrose, Sodium Bicarbonate, Potassium Bicarbonate, Sodium Carbonate, Natural Flavors, Potassium Chloride, Malic Acid, Magnesium Carbonate, Calcium Carbonate, Stevia Leaf Extract, Beet Powder Color, Safflower Oil. Nuun electrolytes contains (per tablet) the following: 3 grams of carbohydrate, calcium (15 mg, 1%DV), sodium (200 mg, 9%DV), potassium (125mg, 3%DV), magnesium (15mg, 4%DV), and chloride (75mg, 3%DV).
Study: NCT05077566

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Exercise at 60% vo2
Description: 15 minutes of exercise at 60% VO2 max.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Exercise at 90% vo2
Description: 15 minutes of exercise at 90% VO2 max.
Study: NCT06496035

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Blood Flow Restriction with low load exercise
Description: Cuff/tourniquet will be applied to proximal leg at hip crease and inflated to 60-80% of limb occlusion pressure to decrease venous blood flow in the limb while performing exercise.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Therapeutic Exercise
Description: Exercise performed at appropriate load as guided by physical therapist
Study: NCT06325189

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Aerobic Interval Training
Description: Aerobic interval training is a cardiovascular exercise that involves short bursts of high-intensity activity followed by a brief rest or low-intensity exercise. It improves cardiovascular fitness, increases lung capacity, and enhances cardiovascular endurance. It also leads to higher calorie expenditure and time efficiency, allowing for faster fitness goals.
Study: NCT04366336

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Blood Flow Restriction Training
Description: Same as Standard PT with the exception that BFRT involves placing the pressure cuff before the start of therapeutic exercises

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Standard Physical Therapy
Description: Therapeutic exercise, including but not limited to: movement re-education, balance, and functional strength training; and Manual Physical Therapy including but not limited to passive range of motion (therapist will move your knee without your help), joint mobilization, soft-tissue mobilization and static stretching
Study: NCT05493176

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Dry immersion
Description: Subjects are immersed up to the neck for 5 days in a specially designed bath filled with tap water.
Study: NCT04804800

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Experimental group 1 : Virtual Reality
Description: Patients benefit from the care recommended by the HAS, the virtual reality program and time for relaxation and body scan.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Experimental group 2 : Virtual Reality + Multi Sensorial Remediation
Description: Patients benefit from the care recommended by the HAS, the virtual reality program, the multisensory remediation, and also the body scan.
Study: NCT04316312

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Threshold inspiratory muscle trainer
Description: Threshold inspiratory muscle trainer will be set between 15% to 30% of maximal inspiratory pressure.
Study: NCT05834231

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Memantine
Description: oral

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: oral
Study: NCT05411536

Intervention type: OTHER
Intervention: Walking trials
Description: All participants will complete a series of walking trials. They will first be requested to perform three practice walks followed by three walking trials on a 7.4m straight level-ground firm walkway (GW) and the other three walking trials on a 7.4m straight foam walkway (FW) in a randomised order. The dimension of the foam walkway in the FW will be 8m (length), 0.8m (width), and 0.3m (height). The starting and finishing lines of the FW will be positioned at 0.3m from each side of the FW's edges. Thus, the lengths of the FW and the GW will be identical (i.e., 7.4m). Participants will be asked to walk 7.4m and stop for each walking trial.~After a 10-minute rest break, participants will perform nine walking trials on the GW and the other nine walking trials on the FW, including three repetitions of three different attentional focus instructions (external focus \[EF\], internal focus \[IF\], and no specific focus \[NF\]) in the GW and FW in a randomised order.

Intervention type: OTHER
Intervention: Walking trials
Description: All participants will complete a series of walking trials. They will first be requested to perform three practice walks followed by three walking trials on a 7.4m straight level-ground firm walkway (GW) and the other three walking trials on a 7.4m straight foam walkway (FW) in a randomised order. The dimension of the foam walkway in the FW will be 8m (length), 0.8m (width), and 0.3m (height). The starting and finishing lines of the FW will be positioned at 0.3m from each side of the FW's edges. Thus, the lengths of the FW and the GW will be identical (i.e., 7.4m). Participants will be asked to walk 7.4m and stop for each walking trial.~After a 10-minute rest break, participants will perform nine walking trials on the GW and the other nine walking trials on the FW, including three repetitions of three different attentional focus instructions (external focus \[EF\], internal focus \[IF\], and no specific focus \[NF\]) in the GW and FW in a randomised order.
Study: NCT06015126

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: metronomic oral vinorelbine plus anlotinib
Description: To clarify the efficacy and safety of metronomic oral vinorelbine plus anlotinib in HER2-negative metastatic breast cancer patients, adding new data for the posterior treatment of HER2-negative advanced breast cancer
Study: NCT05749133

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Anti-GPRC5D CAR-T Cells Injection
Description: This is a3+3dose escalation study, in which three dose groups are set three different dose levels of CAR-T cells: Initial dose group: 3.0×10\^6/kg±20%; Low dose group: 3.0×10\^6/kg±20%; High dose group: 6.0×10\^6/kg±20%. Dose was weight-based.
Study: NCT04631770

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Systemic mediastinal lymph node dissection
Description: Systematic hilar and mediastinal lymph node dissection.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Spared mediastinal lymph node dissection
Description: Mediastinal lymph node is spared in this group.
Study: NCT04854148

Intervention type: OTHER
Intervention: Smartphone Movement Health Assessment
Description: Participants will perform the assessment using an App installed on a smartphone device. Following the smartphone assessment, gold standard clinical assessments will be performed and scored for comparison